Project Grant R21AI180728
Award Date
7/19/24
Completion Date
5/31/26
Dollars Obligated
$336K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This federal Project Grant award for $239,366 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to evaluate the effects of anti-malarial chemoprevention interventions on child growth outcomes in Uganda. Specifically, the study will (1) assess the impact of intermittent preventative treatment in pregnancy (IPTp) and childhood (IPTc) on child growth and (2) investigate the causal pathways through...
The federal Project Grant award of $709,872 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding will support the development and pilot testing of a couple-based intervention to address perinatal depression and improve adherence to prevention of mother-to-child transmission (PMTCT) of HIV in Malawi. The project aims to (1) develop a couple-based intervention using problem-solving...
This $1,303,086 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to evaluate the longitudinal impact of early childhood malaria prevention interventions, including seasonal malaria chemoprevention (SMC) and the RTS,S malaria vaccine, on malaria risk and disease burden in school-age children in Ghana. The primary objectives are to understand the epidemiological impact of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $446,025 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Notre Dame. The grant will fund a 2-year research project to study the impact of spatial repellents, a novel vector control tool, on reducing the prevalence of asymptomatic Plasmodium falciparum infections and malaria transmission potential in western Kenya. The project aims to: 1) quantify reductions in...
This $250,796 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the planning and preparatory activities for a two-part clinical trial to assess the safety, immunogenicity, and efficacy of the PFSPZ-LARC2 malaria vaccine in malaria-exposed adults and children in Burkina Faso. The key products and services to be delivered through this funding include developing the...
This Project Grant award, totaling $648,448.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports research to define the complex genetic basis of Plasmodium falciparum resistance to artemisinin and quinine, as well as identify resistance-refractory therapeutics. Specifically, the research aims to: Investigate the role of candidate genes MRP1 and ARPS10 in mitigating...
This Project Grant award totaling $708,202 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Brown University. The primary objective is to discover antigens from the Plasmodium falciparum malaria parasite that are targets of protective antibody responses, with the goal of developing them as novel blood-stage vaccine candidates. The project will involve conducting a case-control study in...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $206,116 to Oregon Health & Science University (OHSU) to develop new 4-aminoquinoline compounds as potential therapeutics against multi-drug resistant Plasmodium falciparum, the deadliest malaria parasite. The key objectives are to: 1) use an iterative medicinal chemistry approach to optimize the lead...
This $467,400 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a platform for quantifying levels of antimalarial drugs, including lumefantrine, amodiaquine, and piperaquine, in dried blood spot (DBS) samples. The research team at the University of California, San Francisco (UCSF) will employ volumetric absorptive microsampling (VAMS) techniques to collect precise DBS...
This $777,072 five-year Project Grant award under the National Institute of Allergy and Infectious Diseases' (NIAID) Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to develop an understanding of factors that drive the efficacy and resistance acquisition risk for a new class of fast-acting antimalarial drugs called ATP4 inhibitors (ATP4I), including SJ733 which recently completed Phase 2A trials. The research will examine the efficacy and resistance patterns...